281 related articles for article (PubMed ID: 31914821)
1. Development of nano-carriers for
Askarizadeh A; Badiee A; Khamesipour A
Expert Opin Drug Deliv; 2020 Feb; 17(2):167-187. PubMed ID: 31914821
[No Abstract] [Full Text] [Related]
2. Micro/nanoparticle adjuvants for antileishmanial vaccines: present and future trends.
Badiee A; Heravi Shargh V; Khamesipour A; Jaafari MR
Vaccine; 2013 Jan; 31(5):735-49. PubMed ID: 23219436
[TBL] [Abstract][Full Text] [Related]
3. Leishmaniasis: focus on the design of nanoparticulate vaccine delivery systems.
Doroud D; Rafati S
Expert Rev Vaccines; 2012 Jan; 11(1):69-86. PubMed ID: 22149710
[TBL] [Abstract][Full Text] [Related]
4. Not All Antigens Are Created Equally: Progress, Challenges, and Lessons Associated with Developing a Vaccine for Leishmaniasis.
Duthie MS; Reed SG
Clin Vaccine Immunol; 2017 Jul; 24(7):. PubMed ID: 28515135
[TBL] [Abstract][Full Text] [Related]
5. Immunization against leishmaniasis by PLGA nanospheres loaded with an experimental autoclaved Leishmania major (ALM) and Quillaja saponins.
Tafaghodi M; Eskandari M; Kharazizadeh M; Khamesipour A; Jaafari MR
Trop Biomed; 2010 Dec; 27(3):639-50. PubMed ID: 21399606
[TBL] [Abstract][Full Text] [Related]
6. Recent developments in leishmaniasis vaccine delivery systems.
Bhowmick S; Ali N
Expert Opin Drug Deliv; 2008 Jul; 5(7):789-803. PubMed ID: 18590463
[TBL] [Abstract][Full Text] [Related]
7. Induction of protection against leishmaniasis in susceptible BALB/c mice using simple DOTAP cationic nanoliposomes containing soluble Leishmania antigen (SLA).
Firouzmand H; Badiee A; Khamesipour A; Heravi Shargh V; Alavizadeh SH; Abbasi A; Jaafari MR
Acta Trop; 2013 Dec; 128(3):528-35. PubMed ID: 23916506
[TBL] [Abstract][Full Text] [Related]
8. Vaccine candidates against leishmania under current research.
Iborra S; Solana JC; Requena JM; Soto M
Expert Rev Vaccines; 2018 Apr; 17(4):323-334. PubMed ID: 29589966
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic vaccines for leishmaniasis.
Khamesipour A
Expert Opin Biol Ther; 2014 Nov; 14(11):1641-9. PubMed ID: 25077737
[TBL] [Abstract][Full Text] [Related]
10. Delivery systems for Leishmania vaccine development.
Gholami E; Zahedifard F; Rafati S
Expert Rev Vaccines; 2016 Jul; 15(7):879-95. PubMed ID: 26905526
[TBL] [Abstract][Full Text] [Related]
11. Particulate and non-particle adjuvants in Leishmaniasis vaccine designs: A review.
Kelleci K; Allahverdiyev A; Bağirova M; Ihlamur M; Abamor EŞ
J Vector Borne Dis; 2023; 60(2):125-141. PubMed ID: 37417162
[TBL] [Abstract][Full Text] [Related]
12. Liposomal SLA co-incorporated with PO CpG ODNs or PS CpG ODNs induce the same protection against the murine model of leishmaniasis.
Shargh VH; Jaafari MR; Khamesipour A; Jaafari I; Jalali SA; Abbasi A; Badiee A
Vaccine; 2012 Jun; 30(26):3957-64. PubMed ID: 22465747
[TBL] [Abstract][Full Text] [Related]
13. A TLR9-adjuvanted vaccine formulated into dissolvable microneedle patches or cationic liposomes protects against leishmaniasis after skin or subcutaneous immunization.
Lanza JS; Vucen S; Flynn O; Donadei A; Cojean S; Loiseau PM; Fernandes APSM; Frézard F; Moore AC
Int J Pharm; 2020 Aug; 586():119390. PubMed ID: 32540349
[TBL] [Abstract][Full Text] [Related]
14. Visceral leishmaniasis: An overview of vaccine adjuvants and their applications.
Ratnapriya S; Keerti ; Sahasrabuddhe AA; Dube A
Vaccine; 2019 Jun; 37(27):3505-3519. PubMed ID: 31103364
[TBL] [Abstract][Full Text] [Related]
15. Adjuvants and delivery systems based on polymeric nanoparticles for mucosal vaccines.
Jin Z; Gao S; Cui X; Sun D; Zhao K
Int J Pharm; 2019 Dec; 572():118731. PubMed ID: 31669213
[TBL] [Abstract][Full Text] [Related]
16. Vaccination with poly(D,L-lactide-co-glycolide) nanoparticles loaded with soluble
Margaroni M; Agallou M; Athanasiou E; Kammona O; Kiparissides C; Gaitanaki C; Karagouni E
Int J Nanomedicine; 2017; 12():6169-6184. PubMed ID: 28883727
[TBL] [Abstract][Full Text] [Related]
17. In-depth review of delivery carriers associated with vaccine adjuvants: current status and future perspectives.
Zeng Y; Zou F; Xia N; Li S
Expert Rev Vaccines; 2023; 22(1):681-695. PubMed ID: 37496496
[TBL] [Abstract][Full Text] [Related]
18. An overview on the role of silica-based materials in vaccine development.
Navarro-Tovar G; Palestino G; Rosales-Mendoza S
Expert Rev Vaccines; 2016 Nov; 15(11):1449-1462. PubMed ID: 27160927
[TBL] [Abstract][Full Text] [Related]
19. Cross-protective efficacy from a immunogen firstly identified in Leishmania infantum against tegumentary leishmaniasis.
Martins VT; Lage DP; Duarte MC; Costa LE; Chávez-Fumagalli MA; Roatt BM; Menezes-Souza D; Tavares CA; Coelho EA
Parasite Immunol; 2016 Feb; 38(2):108-17. PubMed ID: 26756314
[TBL] [Abstract][Full Text] [Related]
20. Polymeric nanoparticles: potent vectors for vaccine delivery targeting cancer and infectious diseases.
Bolhassani A; Javanzad S; Saleh T; Hashemi M; Aghasadeghi MR; Sadat SM
Hum Vaccin Immunother; 2014; 10(2):321-32. PubMed ID: 24128651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
